Home
Menu
Updates
ARISTO is ranked No. 3 in its Covered market (Source: IQVIA MAT’May’24)ARISTO has launched the World’s No.1 probiotic L. rhamnosus GG as ‘ProGG’ under the technical tie-up with the Innovator Chr. Hansen, DenmarkARISTO continues to be No. 5th company in India as per SMSRC prescription audit data (Nov-Feb’24)ARISTO is ranked No. 4 on CAGR (5 years) among the top 15 companies of the India Pharma Market (Source: IQVIA MAT’May’24)
Aristo-at-a-galance-1
Aristo-at-a-galance-2

ARISTO at a Glance....

CORPORATE IQVIA DATA (CONVERTED IN TO US$)

Revenues ( US $ Million )
:
662.19
Market Share
:
2.90%
Gain in Market Share%
:
-0.14%
Rx Audit Rank (SMSRC) MAT AUG'24
:
5
Growth
:
2.28%
CAGR (5 years)
:
11.06%
Rank in Indian Pharma Market
:
11
Covered Market Size ( US $ Million)
:
10731.68
Covered Market Growth%
:
6
Market Share in Covered Market
:
6.17%
Rank in Covered Market
:
3
Front Line Sales Force
:
5100

Source : Stockist Secondary Audit IMS - MAT FEB'25 Dataset
US$ = 85.61 - (01/04/2025)

Monocef- SB – 250mg, 125mg

MOLECULEBRANDSTRENGTHCOMPOSITIONPACK SIZETHERAPY
Ceftriaxone, SulbactamMonocef- SB250mg, 125mgEach vial contains: Ceftriaxone Sodium equivalent to Ceftriaxone 250mg, Sulbactam Sodium equivalent to Sulbactam 125mgVialAnti-Bacterial Parenteral

© ARISTO Pharmaceuticals Private Limited | Website Maintenance by Website Maintenance Services